ATR
Serine/threonine-protein kinase ATR
As of the edition of 20 October 2026, ATR (serine/threonine-protein kinase ATR, UniProt Q13535) has 8 drugs tested at it and 10 companies on the list, 5 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13535
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 23
- Disease areas
- Cancer; Urinary and reproductive; Lungs and airways; Pregnancy and women's health; Hormones; Skin and connective tissue; Digestive system; Nervous system
- Registered trials of its drugs
- 109
Drugs at this target
| Status | Count |
|---|---|
| Active | 4 |
| Stopped | 4 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ceralasertib | Stopped | Phase 3 | none listed |
| Berzosertib | Active | Phase 2 | none listed |
| Tuvusertib | Active | Phase 2 | none listed |
| Elimusertib | Stopped | Phase 2 | none listed |
| Camonsertib | Active | Phase 2 | none listed |
| M4344 | Stopped | Phase 2 | none listed |
| ATG-018 | Stopped | Phase 1 | none listed |
| YY2201 | Active | Phase 1 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Engaged | 5 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Bayer | Route A |
| Xeno Biosciences | Route A |
The other 7 companies at ATR
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at ATR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.